Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.

Agustín Sancho-SaldañaAnna Gil Sánchez Bibiana Quirant-SanchezLara NoguerasSilvia PeraltaMaria José SolanaCristina González-Mingot Yhovanni GallegoLaura QuibusCristina Ramo-TelloSilvia Presas-RodríguezEva Martínez-CáceresPascual TorresJosé Vicente HervásJoan VallsLuis Brieva

Published in: Journal of clinical medicine (2022)

According to our data, pwMS present a higher risk of COVID-19 infection compared with results obtained from the general population. There is no evidence of a worse COVID-19 outcome in pwMS. DMTs did not significantly change the frequency of COVID-19, except for interferon; however, these findings must be interpreted with caution given the small sample of pwMS taking each DMT.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
electronic health record
dendritic cells
big data
machine learning
artificial intelligence